tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Silexion Announces Positive Preclinical Results for SIL204

Story Highlights
Silexion Announces Positive Preclinical Results for SIL204

Elevate Your Investing Strategy:

Silexion Therapeutics ( (SLXN) ) has provided an update.

On July 9, 2025, Silexion Therapeutics announced positive preclinical results for SIL204, demonstrating significant efficacy in human lung cancer cell lines. The study highlighted SIL204’s potential as a versatile therapeutic for KRAS-driven cancers, supporting its innovative lipid-conjugated delivery system. The company is preparing for a Phase 2/3 clinical trial in 2026 and is conducting additional studies on a new KRAS mutation, which could establish SIL204 as a potential pan-KRAS treatment.

The most recent analyst rating on (SLXN) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Silexion Therapeutics stock, see the SLXN Stock Forecast page.

Spark’s Take on SLXN Stock

According to Spark, TipRanks’ AI Analyst, SLXN is a Underperform.

Silexion Therapeutics has significant financial difficulties with zero revenue and negative equity, posing major risks. Technical analysis indicates a bearish trend, and speculative valuation metrics reflect the high-risk nature of the stock. However, promising corporate developments, such as the SIL204 partnership and positive preclinical results, offer potential upside if clinical success is achieved.

To see Spark’s full report on SLXN stock, click here.

More about Silexion Therapeutics

Silexion Therapeutics is a clinical-stage biotechnology company focused on developing RNA interference (RNAi) therapies to treat solid tumors driven by KRAS mutations, which are common oncogenic drivers in human cancers. The company is advancing its next-generation siRNA candidate, SIL204, and has shown promising results in preclinical studies.

Average Trading Volume: 1,660,362

Technical Sentiment Signal: Sell

Current Market Cap: $7.08M

For an in-depth examination of SLXN stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1